Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Shares of US clinical-stage biotech Apogee Therapeutics closed down 17.3% at $39.24 yesterday, despite announcing positive 16 ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Apogee Therapeutics Inc. plans to enter a crowded atopic dermatitis market with established drugs, such as Dupixent (dupilumab, Regeneron Pharmaceuticals Inc. and Sanofi SA) and Ebglyss ...

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Protagonist is directly going up against Eli Lilly, which is advancing retatrutide, also a triple-G agonist, in a Phase II ...

Despite being on the market for less than three years, GLP-1 medicines, Mounjaro and Zepbound, became key top-line drivers ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

Eli Lilly's experimental obesity therapy bimagrumab drew mixed reactions from Wall Street after the company recently ...